Key result
Pharmacological inhibition or genetic ablation of PARP-1 provides protection from tissue injury in oxidative stress-related diseases and benefits cancer treatment through multiple mechanisms.
PARP-1 plays a critical role in transcriptional regulation, DNA repair, and cell death, making its inhibition a promising strategy for treating oxidative stress-related diseases and cancer.
PARP-1 inhibition may benefit oxidative stress diseases and cancer; leaves open randomized trials before clinical adoption.
Post-translational modification of proteins by poly(ADP-ribosyl)ation is involved in the regulation of a number of biological functions. While an 18 member superfamily of poly(ADP-ribose) polymerases (PARP)s has been described PARP-1 accounts for more than 90% of the poly(ADP-ribosyl)ating capacity of the cells. PARP-1 act as a DNA nick sensor and is activated by DNA breaks to cleave NAD(+) into nicotinamide and ADP-ribose to synthesize long branching poly(ADP-ribose) polymers (PAR) covalently attached to nuclear acceptor proteins. Whereas activation of PARP-1 by mild genotoxic stimuli facilitate DNA repair and cell survival, severe DNA damage triggers different pathways of cell death including PARP-mediated cell death through the translocation of apoptosis inducing factor (AIF) from the mitochondria to the nucleus. PAR and PARP-1 have also been described as having a function in transcriptional regulation through their ability to modify chromatin-associated proteins and as a cofactor of different transcription factors, most notably NF-kappaB and AP-1. Pharmacological inhibition or genetic ablation of PARP-1 not only provided remarkable protection from tissue injury in various oxidative stress-related disease models but it result in a clear benefit in the treatment of cancer by different mechanisms including selective killing of homologous recombination-deficient tumor cells, down regulation of tumor-related gene expression and decrease in the apoptotic threshold in the co-treatment with chemo and radiotherapy. We will summarize in this review the current findings and concepts for the role of PARP-1 and poly(ADP-ribosyl)ation in the regulation of transcription, oxidative stress and carcinogenesis.
No takes yet. Share an insight, caveat, or question.
Aguilar‐Quesada et al. (2007) conducted a review in Carcinogenesis and Inflammation. PARP-1 inhibition or genetic ablation was evaluated. Pharmacological inhibition or genetic ablation of PARP-1 provides protection from tissue injury in oxidative stress-related diseases and benefits cancer treatment through multiple mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: